Use of tenofovir disoproxil fumarate is associated with a lower risk of hepatocellular carcinoma than entecavir in patients with chronic hepatitis B

Abstract

In patients with chronic hepatitis B (CHB), entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are equally recommended as first-line treatment by the international guidelines. These two drugs have shown similar short and intermediate clinical outcomes, including virologic, biochemical, and histologic responses. However, there is considerable controversy as to whether ETV and TDF differ in reducing the risk of hepatocellular carcinoma (HCC) in patients with CHB despite many observational studies and meta-analyses being published. In this review, we summarize recent evidence comparing the preventive effects of these two drugs against HCC from the perspective that TDF is associated with a lower risk of HCC compared with ETV in patients with CHB.

Keywords

Hepatocellular carcinoma / hepatitis b virus / tenofovir disoproxil fumarate / entecavir / prevention

References

[1] Schweitzer A,Mikolajczyk RT,Ott JJ.Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.Lancet2015;386:1546-55

[2] Razavi-shearer D,Nguyen MH.Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.Lancet Gastroenterol Hepatol2018;3:383-403

[3] Vos T,Abate KH.Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.Lancet2017;390:1211-59 PMCID:PMC5605509

[4] Llovet JM,Villanueva A.Hepatocellular carcinoma.Nat Rev Dis Primers2021;7:6

[5] Sepanlou SG,Bisignano C.The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet Gastroenterol Hepatol2020;5:245-66 PMCID:PMC7026710

[6] Chen CJ,Su J.REVEAL-HBV Study GroupRisk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.JAMA2006;295:65-73

[7] Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B.Clin Mol Hepatol2019;25:93-159

[8] Association for the Study of the Liver, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.J Hepatol2017;67:370-98

[9] Terrault NA,McMahon BJ.Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.Hepatology2018;67:1560-99 PMCID:PMC5975958

[10] Sarin SK,Lau GK.Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Hepatol Int2016;10:1-98 PMCID:PMC4722087

[11] Ahn J,Lee HM.Lower observed hepatocellular carcinoma incidence in chronic hepatitis B patients treated with entecavir: results of the ENUMERATE Study.Am J Gastroenterol2016;111:1297-304

[12] Liu K,Le A.Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis.Aliment Pharmacol Ther2019;50:1037-48

[13] Choi J,Lee J,Ko MJ.Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a korean nationwide cohort study.JAMA Oncol2019;5:30-6 PMCID:PMC6439769

[14] Yip TC,Chan HL,Lui GC.Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China.Gastroenterology2020;158:215-25.e6

[15] Ha Y,Kim MN,Hwang SG.Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate.Sci Rep2020;10:13537 PMCID:PMC7419516

[16] Kim SU,Lee HA.A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.J Hepatol2019;71:456-64

[17] Lee SW,Lee HL.Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.Gut2020;69:1301-8 PMCID:PMC7306978

[18] Papatheodoridis GV,Idilman R.Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.J Hepatol2020;73:1037-45

[19] Chen CH,Wang JH.Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan - a retrospective study.Am J Cancer Res2020;10:3882-95 PMCID:PMC7716174

[20] Kim R,Lu M.IDDF2020-ABS-0057 risk of incident hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) virus-infected patients treated with tenofovir disoproxil fumarate (TDF) versus entecavir (ETV): a US administrative claims analysis.Gut2020;69:A73

[21] Zhang M,Liu H.Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection.Infect Agent Cancer2018;13:19 PMCID:PMC5994044

[22] Ge Z,Qiao B,Zhang H.Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality.Medicine (Baltimore)2020;99:e21454 PMCID:PMC7593059

[23] Choi J,Lim YS.Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.Hepatology2021;73:661-73

[24] Imamura H,Tanaka E.Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.J Hepatol2003;38:200-7

[25] Chen YJ,Chen JT.Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma.Gastroenterology2000;119:431-40

[26] Chang TS,Chen WM.Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B.Sci Rep2021;11:1365 PMCID:PMC7809351

[27] Ha I,Jang ES,Kim JW.Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: a propensity score matching analysis.J Gastroenterol Hepatol2020;35:1774-81

[28] Shin JW,Jung SW.Comparable incidence of hepatocellular carcinoma in chronic hepatitis B Patients treated with entecavir or tenofovir.Dig Dis Sci2021;66:1739-50

[29] Hsu YC,Chen CH.Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B.Am J Gastroenterol2020;115:271-80

[30] Oh H,Jun DW.Long-Term Safety of Entecavir and Tenofovir in Patients With Treatment-Naive Chronic Hepatitis B Virus (CHB) Infection (SAINT) StudyNo difference in incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection treated with entecavir vs tenofovir.Clin Gastroenterol Hepatol2020;18:2793-802.e6

[31] S; ANRS/AFEF study group. Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort.Aliment Pharmacol Ther2021;53:616-29

[32] Su F,Ioannou GN.No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.Gut2021;70:370-8

[33] Tseng C,Chen T.Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2020;5:1039-52

[34] Yuan J,Hao FB,Wang CR.No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis.Aging (Albany NY)2021;13:7147-65 PMCID:PMC7993671

[35] Choi WM,Lim YS.Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis.Clin Gastroenterol Hepatol2021;19:246-58.e9

[36] Flemming JA.Tenofovir vs entecavir for hepatocellular carcinoma prevention in patients with chronic hepatitis B: one of these things is not like the other.JAMA Oncol2019;5:17-8

[37] Gu L,Shen Z.Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis.J Gastroenterol Hepatol2020;35:1467-76

[38] Cheung KS,Liu SH.Entecavir vs tenofovir in hepatocellular carcinoma prevention in chronic hepatitis B infection: a systematic review and meta-analysis.Clin Transl Gastroenterol2020;11:e00236 PMCID:PMC7544163

[39] Jeong S,Park SM.Differential effectiveness of tenofovir and entecavir for prophylaxis of hepatocellular carcinoma in chronic hepatitis B patients depending on coexisting cirrhosis and prior exposure to antiviral therapy: a systematic review and meta-analysis.J Clin Gastroenterol2021;55:e77-86

[40] Li M,Wu S.Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis.Hepatol Int2020;14:105-14

[41] Lam YF,Wong D.Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels.Clin Transl Gastroenterol2017;8:e125 PMCID:PMC5666122

[42] Lim TH,Moyes C,Cunningham C.Serological and clinical outcomes of horizontally transmitted chronic hepatitis B infection in New Zealand Māori: results from a 28-year follow-up study.Gut2015;64:966-72

[43] Papatheodoridis GV,Dalekos GN.The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.Hepatology2017;66:1444-53

[44] Kim WR,Berg T.Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.Cancer2015;121:3631-8

[45] Udompap P.Development of Hepatocellular Carcinoma in Patients With Suppressed Viral Replication: Changes in Risk Over Time.Clin Liver Dis (Hoboken)2020;15:85-90 PMCID:PMC7098665

[46] Chen MB,Zheng QH.Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: a systematic review and meta-analysis.PLoS One2019;14:e0224773 PMCID:PMC6872143

[47] Koike K,Ito H,Sugiura W.Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naïve chronic hepatitis B patients.Hepatol Res2018;48:59-68

[48] Abushahba W,Castaneda I.Antitumor activity of type I and type III interferons in BNL hepatoma model.Cancer Immunol Immunother2010;59:1059-71 PMCID:PMC4699672

[49] Sato A,Hata M,Murakami T.Antitumor activity of IFN-lambda in murine tumor models.J Immunol2006;176:7686-94

[50] Murata K,Matsumoto A.Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.Gut2018;67:362-71

[51] Zhang Z,Yang J,Huang Y.The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis.BMC Cancer2019;19:511 PMCID:PMC6542001

[52] Wang X,Dang Z.Nucleos(t)ide analogues for reducing hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis.Gut Liver2020;14:232-47 PMCID:PMC7096226

[53] Dave S,Murad MH.Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and meta-analysis.Hepatology2021;73:68-78 PMCID:PMC8022893

[54] Liu H,Hayden JC,Rahmani J.Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B: a systematic review and meta-analysis.Liver Cancer2020;9:468-76 PMCID:PMC7506291